MedTrace Logo

Efficacy of Dun Ye Guan Xin Ning Tablet in Patients With Stable Angina Pectoris

NCT03198091 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2017-06-23

No results posted yet for this study

Summary

This registry is designed to investigate factors affecting the efficacy of Dun Ye Guan Xin Ning tablet on patients with stable angina. The potential hypothesis is that Dun Ye Guan Xin Ning has a better effect on different subgroup patients with certain characteristics.

Conditions

Interventions

DRUG

Dun Ye Guan Xin Ning

Dun Ye Guan Xin Ning tablet 320 mg orally every time and 3 times per day for 6 months.

Sponsors & Collaborators

  • Jiangsu Wanbang Pharmaceutical Marketing Co.,Ltd.

    collaborator UNKNOWN

  • Peking University First Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-30
Primary Completion
2018-06-01
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03198091 on ClinicalTrials.gov